canakinumab versus placebo | |||
CANTOS, 2017 NCT01327846 | Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months versus placebo | Stable Post-myocardial Infarction Patients With Elevated hsCRP | double-blind Follow-up duration: 36 months |
in first
in second